Cardiavent Inc.
3991 Ramsgate Ct.
Ann Arbor, MI 48013
rsrobsim@gmail.com
Cardiavent Inc.
The companies’ strength centers on our experience and high technology.
- Cardiavent founded in 2009 to develop CARD-024 for renal and cardiovascular disease
- CARD-024 discovered based on understanding of vitamin D metabolism
- Chemical structure modifications to eliminate absorption from duodenal enterocytes, and decrease induction of intestinal calcium absorption.
- Preclinical and Phase 1 studies demonstrate biologic activity without induction of hypercalcemia.
- Potential best-in-class treatment for secondary hyperparathyroidism (> $700 million market in the US in 2012):
- Addresses main toxicity issue with current therapies.
- Rapid development pathway to NDA approval.
- Broad therapeutic index supports potential for superior efficacy in reaching target PTH levels and for less frequent safety monitoring.
- Potential best-in-class treatment for TGF-beta induced fibrosis in Crohn's Disease.
- Inhibits TGF-beta induced markers of intestinal fibrosis alpha-SMA and pFAK
- Cardiavent founded in 2009 to develop CARD-024 for renal and cardiovascular disease
- CARD-024 discovered based on understanding of vitamin D metabolism
- Chemical structure modifications to eliminate absorption from duodenal enterocytes, and decrease induction of intestinal calcium absorption.
- Preclinical and Phase 1 studies demonstrate biologic activity without induction of hypercalcemia.
- Potential best-in-class treatment for secondary hyperparathyroidism (> $700 million market in the US in 2012):
- Addresses main toxicity issue with current therapies.
- Rapid development pathway to NDA approval.
- Broad therapeutic index supports potential for superior efficacy in reaching target PTH levels and for less frequent safety monitoring.
- Potential best-in-class treatment for TGF-beta induced fibrosis in Crohn's Disease.
- Inhibits TGF-beta induced markers of intestinal fibrosis alpha-SMA and pFAK
